Study at KTH’s Cell Technology Group (CETEG) builds on earlier tests showing up to 25% higher IgG productivity

Gothenburg, Sweden, November 10, 2026. VentriLabs has received funding from Vinnova, Sweden’s innovation agency, to evaluate its DuaFLO® BioPump in high cell density perfusion cultivation. The project will be carried out at the Cell Technology Group (CETEG)​ at KTH Royal Institute of Technology in Stockholm, led by Professor Veronique Chotteau, a pioneer in the field.

Perfusion is gaining ground in biopharmaceutical manufacturing, as it enables higher volumetric productivity within a smaller production footprint. In many perfusion setups, cells are recirculated continuously through an external cell retention loop, which makes the pump a critical part of the process. Shear forces and pulsation can damage cells and reduce their viability and productivity, and the effect becomes more pronounced as cell densities increase.

The DuaFLO® BioPump was developed to address this challenge. It delivers a gentle, non-pulsatile flow that moves cells without damaging them, including in high-density cultures where conventional pump technologies become a limiting factor. In previous independent testing in a perfusion process with CHO cells, DuaFLO® delivered up to 25% higher IgG productivity than a state-of-the-art pump. For manufacturers, this can mean healthier cultures, more stable processes and better conditions for consistent product quality.

Within the project, CETEG will run perfusion cultivations of mammalian cells in which the DuaFLO® BioPump is tested against reference pumps under representative process conditions. The aim is to generate comparative data on cell growth, viability and productivity.

“The data from this project will give customers and OEM partners a strong basis for assessing DuaFLO® in their own processes. Working with Professor Chotteau and her team, internationally recognized experts in high cell density perfusion, adds significant weight to those results,” says Robin Öz, CEO of VentriLabs.

“As cell densities increase, gentle cell handling becomes critical to maintaining culture performance. Testing novel equipment under industrially relevant conditions is central to our work at CETEG, and we look forward to exploring the DuaFLO® BioPump together with VentriLabs,” says Professor Chotteau.

The project is funded through Vinnova’s call “Nyttja infrastrukturer för innovation inom life science”. VentriLabs will share results as the work progresses.

About VentriLabs

Ventri Labs AB, founded in 2023 and based in Gothenburg, Sweden, develops novel pump technology for bioprocessing. Its DuaFLO® BioPump provides gentle, non-pulsatile flow for intensified bioprocesses, cell culture and the handling of sensitive biological fluids. It is protected by two granted patents, with further patent applications pending. For more information, visit www.ventrilabs.com.

About CETEG, KTH

The Cell Technology Group (CETEG) at KTH Royal Institute of Technology develops cell-based processes for biologics production, with a focus on high cell density perfusion of CHO and HEK293 cells. Its head, Professor Veronique Chotteau, also directs AdBIOPRO, Vinnova’s Competence Centre for Advanced BioProduction by Continuous Processing.

Media contact

Robin Öz, CEO, Ventri Labs AB

robin.oz@ventrilabs.com

+46 (0) 300 56 65 20